Liselotte Nilsson
Sales & Marketing chez CLINICAL LASERTHERMIA SYSTEMS AB
Profil
Liselotte Nilsson is currently the Vice President-Marketing at Clinical Laserthermia Systems AB since 2021.
Prior to this, she worked as the Head-Marketing at Phase Holographic Imaging AB, Marketing Manager at ProstaLund AB, and Marketing Manager at Svar Life Science AB.
Postes actifs de Liselotte Nilsson
| Sociétés | Poste | Début |
|---|---|---|
| CLINICAL LASERTHERMIA SYSTEMS AB | Sales & Marketing | 01/01/2021 |
Anciens postes connus de Liselotte Nilsson
| Sociétés | Poste | Fin |
|---|---|---|
| PROSTALUND AB | Sales & Marketing | - |
Svar Life Science AB
 Svar Life Science AB Miscellaneous Commercial ServicesCommercial Services Svar Life Science AB is a Swedish company that provides GMP and non-GMP bioassay services for drug development. The private company is based in Malmö, Sweden. The company specializes in using activity biomarkers to determine if deficiencies, overactivation, or dysregulation in the complement system are causing or contributing to a person's disease or condition. The company offers method development, qualification, validation, and method improvements throughout the drug development lifecycle. Anne Thjømøe has been the CEO of the company since 2022. | Sales & Marketing | - |
| PHASE HOLOGRAPHIC IMAGING PHI AB | Sales & Marketing | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CLINICAL LASERTHERMIA SYSTEMS AB | Health Technology |
| PHASE HOLOGRAPHIC IMAGING PHI AB | Health Technology |
| PROSTALUND AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
Svar Life Science AB
Svar Life Science AB Miscellaneous Commercial ServicesCommercial Services Svar Life Science AB is a Swedish company that provides GMP and non-GMP bioassay services for drug development. The private company is based in Malmö, Sweden. The company specializes in using activity biomarkers to determine if deficiencies, overactivation, or dysregulation in the complement system are causing or contributing to a person's disease or condition. The company offers method development, qualification, validation, and method improvements throughout the drug development lifecycle. Anne Thjømøe has been the CEO of the company since 2022. | Commercial Services |
